Abstract |
Uveitis is the third leading cause of preventable blindness in the U.S. Topical administration of corticosteroids remains the mainstay in the management of acute autoimmune anterior uveitis. Difluprednate 0.05% ophthalmic emulsion is a potent new topical corticosteroid that exhibits enhanced penetration, better bioavailability, rapid local metabolism and strong efficacy, with a low incidence of adverse effects. In June 2008, difluprednate ophthalmic emulsion 0.05% gained FDA approval in the U.S. for the treatment of postoperative ocular inflammation and pain. Recently, a multicenter, randomized clinical trial showed difluprednate to be noninferior to prednisolone acetate 1% dosed twice as often, the current standard of care for the acute management of endogenous uveitis in the U.S. Furthermore, difluprednate proved to have a comparable safety profile. Here, we review difluprednate pharmacokinetics, ocular indications, animal studies, as well as the results of the clinical trials conducted to date in the U.S.
|
Authors | L Mulki, C S Foster |
Journal | Drugs of today (Barcelona, Spain : 1998)
(Drugs Today (Barc))
Vol. 47
Issue 5
Pg. 327-33
(May 2011)
ISSN: 1699-3993 [Print] Spain |
PMID | 22013563
(Publication Type: Journal Article, Review)
|
Copyright | Copyright 2011 Prous Science, S.A.U. or its licensors. All rights reserved. |
Chemical References |
- Fluprednisolone
- difluprednate
|
Topics |
- Animals
- Clinical Trials as Topic
- Endophthalmitis
(drug therapy)
- Fluprednisolone
(adverse effects, analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)
- Humans
|